Newsroom

INDIANAPOLIS, Ind.--(BUSINESS WIRE)--HealthNet and AndHealth celebrated the ribbon cutting of the newly opened HealthNet Pharmacy this week, marking a major investment in affordable pharmacy access, integrated specialty care, and medication support services for patients across Central Indiana. The new pharmacy is located inside HealthNet Specialty Care at Barrington Health & Dental Center on Indianapolis’ east side and expands the organization’s ability to serve patients facing rising barri...

SAN MATEO, Kalifornien--(BUSINESS WIRE)--Die Baszucki Group gab heute bekannt, dass sie eine Förderung in Höhe von 1,17 Millionen Pfund für eine randomisierte kontrollierte Studie an der Universität Oxford bereitstellt, in der die Durchführbarkeit, Sicherheit und Wirksamkeit einer ketogenen Diät bei Patienten mit einem hohen klinischen Psychoserisiko (CHR-P) untersucht werden soll. Die Forscher werden untersuchen, inwieweit diese Ernährungstherapie die geistige und körperliche Gesundheit der Pa...

SAN MATEO, Californie--(BUSINESS WIRE)--Baszucki Group a annoncé aujourd’hui l’octroi d’une subvention de 1,17 million GBP destinée à financer un essai contrôlé randomisé qui sera mené à l’université d’Oxford. Cet essai aura pour but d’évaluer la faisabilité, la sécurité et l’efficacité d’un régime cétogène chez des patients présentant un haut risque clinique de psychose (clinical high risk of psychosis CHR-P). Les chercheurs évalueront la capacité de cette thérapie nutritionnelle à améliorer l...

AUSTIN, Texas--(BUSINESS WIRE)--Amy Porterfield, John Lee, Dan Buettner, Shawn Johnson East, and Andrew East to headline KW’s CEO Summit....

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:   Millennium International Management LP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:   Millennium International Management LP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:   Millennium International Management LP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:   Millennium International Management LP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:   Millennium International Management LP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...

AMSTERDAM--(BUSINESS WIRE)--Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat)...